Cargando…
Novel Therapies for Alport Syndrome
Alport syndrome (AS) is a hereditary kidney disease associated with proteinuria, hematuria and progressive kidney failure. It is characterized by a defective glomerular basement membrane caused by mutations in type IV collagen genes COL4A3/A4/A5 which result in defective type IV collagen α3, α4, or...
Autores principales: | Chavez, Efren, Rodriguez, Juanly, Drexler, Yelena, Fornoni, Alessia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081811/ https://www.ncbi.nlm.nih.gov/pubmed/35547199 http://dx.doi.org/10.3389/fmed.2022.848389 |
Ejemplares similares
-
Clinical trial recommendations for potential Alport syndrome therapies
por: Weinstock, B. André, et al.
Publicado: (2020) -
Adenine crosses the biomarker bridge: from ‘omics to treatment in diabetic kidney disease
por: Drexler, Yelena, et al.
Publicado: (2023) -
Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome
por: Ge, Mengyuan, et al.
Publicado: (2023) -
Editorial: Collagen IV nephropathies: Alport syndrome and beyond
por: Borza, Dorin-Bogdan, et al.
Publicado: (2022) -
Role of Sphingolipid Signaling in Glomerular Diseases: Focus on DKD and FSGS
por: Mitrofanova, Alla, et al.
Publicado: (2020)